163 related articles for article (PubMed ID: 34527317)
1. CHMP4C regulates lung squamous carcinogenesis and progression through cell cycle pathway.
Liu B; Guo S; Li GH; Liu Y; Liu XZ; Yue JB; Guo HY
J Thorac Dis; 2021 Aug; 13(8):4762-4774. PubMed ID: 34527317
[TBL] [Abstract][Full Text] [Related]
2. PSMA1, a Poor Prognostic Factor, Promotes Tumor Growth in Lung Squamous Cell Carcinoma.
Liu Z; Wang W; Zhou Y; Li L; Zhou W
Dis Markers; 2023; 2023():5386635. PubMed ID: 36776923
[TBL] [Abstract][Full Text] [Related]
3. DNA damage repair gene signature model for predicting prognosis and chemotherapy outcomes in lung squamous cell carcinoma.
Wang X; Huang Z; Li L; Wang G; Dong L; Li Q; Yuan J; Li Y
BMC Cancer; 2022 Aug; 22(1):866. PubMed ID: 35941578
[TBL] [Abstract][Full Text] [Related]
4. Construction and Validation of Prognostic Regulation Network Based on RNA-Binding Protein Genes in Lung Squamous Cell Carcinoma.
Zhao S; Liu Q; Li J; Hu C; Cao F; Ma W; Gao J
DNA Cell Biol; 2021 Dec; 40(12):1563-1583. PubMed ID: 34931870
[TBL] [Abstract][Full Text] [Related]
5. Identification of key genes associated with progression and prognosis for lung squamous cell carcinoma.
Ma X; Ren H; Peng R; Li Y; Ming L
PeerJ; 2020; 8():e9086. PubMed ID: 32411535
[TBL] [Abstract][Full Text] [Related]
6. Systematic analysis identifies three-lncRNA signature as a potentially prognostic biomarker for lung squamous cell carcinoma using bioinformatics strategy.
Hu J; Xu L; Shou T; Chen Q
Transl Lung Cancer Res; 2019 Oct; 8(5):614-635. PubMed ID: 31737498
[TBL] [Abstract][Full Text] [Related]
7. A Combined RNA Signature Predicts Recurrence Risk of Stage I-IIIA Lung Squamous Cell Carcinoma.
Sun L; Li J; Li X; Yang X; Zhang S; Wang X; Wang N; Xu K; Jiang X; Zhang Y
Front Genet; 2021; 12():676464. PubMed ID: 34194476
[TBL] [Abstract][Full Text] [Related]
8. A new risk model for CSTA, FAM83A, and MYCT1 predicts poor prognosis and is related to immune infiltration in lung squamous cell carcinoma.
Ding Y; Bian TT; Li QY; He JR; Guo Q; Wu CY; Chen SS
Am J Transl Res; 2022; 14(11):7705-7725. PubMed ID: 36505278
[TBL] [Abstract][Full Text] [Related]
9. Identification of lncRNA biomarkers in lung squamous cell carcinoma using comprehensive analysis of lncRNA mediated ceRNA network.
Li R; Yang YE; Jin J; Zhang MY; Liu X; Liu XX; Yin YH; Qu YQ
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3246-3258. PubMed ID: 31364871
[TBL] [Abstract][Full Text] [Related]
10. A Systematic Analysis of Dysregulated Long Non-Coding RNAs/microRNAs/mRNAs in Lung Squamous Cell Carcinoma.
Zhang TJ; Cao JS; Li Q; An GS; Ni JH; Jia HT; Li SY
Am J Med Sci; 2020 Dec; 360(6):701-710. PubMed ID: 33012486
[TBL] [Abstract][Full Text] [Related]
11. A Novel Pyroptosis-Related Gene Signature for Early-Stage Lung Squamous Cell Carcinoma.
Li X; He J
Int J Gen Med; 2021; 14():6439-6453. PubMed ID: 34675612
[TBL] [Abstract][Full Text] [Related]
12. Tumor mutation burden (TMB)-associated signature constructed to predict survival of lung squamous cell carcinoma patients.
Yan D; Chen Y
Sci Rep; 2021 Apr; 11(1):9020. PubMed ID: 33907270
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the Role and Regulation Mechanism of hsa-miR-147b in Lung Squamous Cell Carcinoma Based on The Cancer Genome Atlas Database.
Ke D; Guo Q; Fan TY; Xiao X
Cancer Biother Radiopharm; 2021 Apr; 36(3):280-291. PubMed ID: 33112657
[No Abstract] [Full Text] [Related]
14. LINC00628 is differentially expressed between lung adenocarcinoma and squamous cell carcinoma and is associated with the prognosis of NSCLC.
Liu T; Xu S; Liu X
Oncol Lett; 2022 Feb; 23(2):55. PubMed ID: 34992687
[TBL] [Abstract][Full Text] [Related]
15. Identification of Survival-Associated Alternative Splicing Signatures in Lung Squamous Cell Carcinoma.
Liu Y; Jia W; Li J; Zhu H; Yu J
Front Oncol; 2020; 10():587343. PubMed ID: 33117720
[No Abstract] [Full Text] [Related]
16. Identification and validation of an individualized prognostic signature of lung squamous cell carcinoma based on ferroptosis-related genes.
Diao X; Guo C; Liu L; Wang G; Li S
Thorac Cancer; 2021 Dec; 12(23):3236-3247. PubMed ID: 34672420
[TBL] [Abstract][Full Text] [Related]
17. Identification of a seven-miRNA signature as prognostic biomarker for lung squamous cell carcinoma.
Gao X; Wu Y; Yu W; Li H
Oncotarget; 2016 Dec; 7(49):81670-81679. PubMed ID: 27835574
[TBL] [Abstract][Full Text] [Related]
18. The necroptosis signature and molecular mechanism of lung squamous cell carcinoma.
Song GQ; Wu HM; Ji KJ; He TL; Duan YM; Zhang JW; Hu GQ
Aging (Albany NY); 2023 Nov; 15(22):12907-12926. PubMed ID: 37976123
[TBL] [Abstract][Full Text] [Related]
19. Predicting the Lung Squamous Cell Carcinoma Diagnosis and Prognosis Markers by Unique DNA Methylation and Gene Expression Profiles.
Wang W; Wang S; Chu X; Liu H; Xiang M
J Comput Biol; 2020 Jul; 27(7):1041-1054. PubMed ID: 31710242
[TBL] [Abstract][Full Text] [Related]
20. GABRP is a Promising Prognostic Biomarker and Associated with Immune Cell Infiltration in Lung Squamous Cell Carcinoma.
Fu J; Lin J; Zeng X; Li G; Wei Y; Xian L
Pharmgenomics Pers Med; 2023; 16():357-371. PubMed ID: 37091829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]